Ivosidenib is a targeted therapy categorized as an isocitrate dehydrogenase-1 (IDH1) inhibitor, primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) and cholangiocarcinoma… Read more






Ivosidenib is a targeted therapy categorized as an isocitrate dehydrogenase-1 (IDH1) inhibitor, primarily used in the treatment of relapsed or refractory acute myeloid leukemia (AML) and cholangiocarcinoma harboring susceptible IDH1 mutations. This collection provides high-quality reference standards for Ivosidenib, including its related impurities, stereoisomers, and synthetic precursors. Pharmaceutical laboratories utilize these materials for comprehensive impurity profiling and to support the development and validation of sensitive analytical methods, such as HPLC or LC-MS. Furthermore, the inclusion of stable isotope labelled compounds provides reliable internal standards necessary for accurate quantitative analysis during drug substance and drug product quality control. By facilitating precise identification and quantification of degradation products and metabolites, these standards support regulatory compliance and ensure the efficacy and safety of pharmaceutical formulations throughout the drug development lifecycle.